Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Metacrine, Inc. | 103,499 | reported | 26 Jan 2023 | tx 3+421,106−107,054 |
| PhaseBio Pharmaceuticals Inc | 7,059 | reported | 20 May 2021 | tx 6+143,059 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 26 Jan 2023 | SALE | Metacrine, Inc. | 107,054 | 0.41 USD | |
| 27 Feb 2022 | GRANT_AWARD | Metacrine, Inc. | 210,553 | 0.00 USD | |
| 27 Feb 2022 | GRANT_AWARD | Metacrine, Inc. | 210,553 | 0.00 USD | deriv |
| 20 May 2021 | GRANT_AWARD | PhaseBio Pharmaceuticals Inc | 2,897 | 2.80 USD | |
| 05 Feb 2021 | GRANT_AWARD | PhaseBio Pharmaceuticals Inc | 36,000 | 0.00 USD | deriv |
| 20 Nov 2020 | GRANT_AWARD | PhaseBio Pharmaceuticals Inc | 2,662 | 3.00 USD | |
| 12 Feb 2020 | GRANT_AWARD | PhaseBio Pharmaceuticals Inc | 55,000 | 0.00 USD | deriv |
| 27 Feb 2019 | GRANT_AWARD | PhaseBio Pharmaceuticals Inc | 45,000 | 0.00 USD | deriv |
| 11 Dec 2018 | PURCHASE | PhaseBio Pharmaceuticals Inc | 1,500 | 3.88 USD |